. Author manuscript; available in PMC: 2011 Oct 1.

Published in final edited form as: Clin Nutr. 2010 Mar 5;29(5):646–653. doi: 10.1016/j.clnu.2010.02.003

Table 1.

Effect of rosiglitazone and abscisic acid (ABA) combination treatment on body and organ weights.^a,^b,^c

Diet	Initial body weight (g)	Final body weight (g)	Ab. WAT% Body Weight	Sc.WAT% Body Weight	Liver% Body Weight
No ABA
Control	42.6 ± 3.2	49.6 ± 1.8^a	7.2 ± 0.61^c	2.4 ± 0.48	6.2 ± 0.51^a
Roslo	42.0 ± 4.5	56.4± 2.4^b ^c	6.7 ± 0.61^b ^c	2.4 ± 0.43	9.2 ± 0.51^b
Roshi	40.6 ± 4.5	64.4 ± 2.4^d	4.6 ± 0.61^a	3.2 ± 0.43	6.7 ± 2.3^a
With ABA
Control	41.3 ± 4.5	53.0 ± 2.7^a ^b	4.7 ± 0.68^a	2.8 ± 0.48	6.7 ± 0.56^a
Roslo	41.1 ± 4.5	51.6 ± 2.4^a ^b	5.4 ± 0.61^a ^b	2.6 ± 0.43	9.3 ± 0.51^b
Roshi	39.7± 4.5	62.6 ± 2.4^c^d	4.5 ± 0.61^a	3.5 ± 0.43	6.7 ± 51^a
P-value for rosiglitazone	0.94	<0.0001	0.03	0.11	<0.0001
P-value for ABA	0.70	0.59	0.02	0.46	0.77
P-value for interaction	0.99	0.23	0.18	0.98	0.81

Organs were excised and weighed on day 60 of experiment.

Least squares means values in a column with a pound sign are significantly different (P < 0.05).

P-value of main effects of rosiglitazone treatments, ABA, and rosiglitazone and ABA combinations during the 60-day period. Data were analyzed as a completely randomized design.